BACKGROUND Subacute cutaneous lupus erythematosus is a nonscarring, non-atrophy-producing photosensitive cutaneous disorder. Half of the patients have 4 or more of the criteria for classification as systemic lupus erythematosus. In some patients, drugs induce or exacerbate the cutaneous disease. OBSERVATION We describe 5 patients who had either an exacerbation or a new onset of subacute cutan...

INTRODUCTION Systemic lupus erythematosus is a multi-system connective tissue disorder. Peripheral neuropathy is a known and underestimated complication in systemic lupus erythematosus. Ganglionopathy manifests when neuronal cell bodies in the dorsal root ganglion are involved. Autoimmune disorders are a known etiology, with systemic lupus erythematosus being a rare cause. CASE PRESENTATION A...

Chilblain lupus erythematosus is a rare form of cutaneous lupus erythematosus characterized by bluish red infiltrates in acral locations of the body mostly affecting middle-aged women. We recently described a familial form of chilblain lupus manifesting in early childhood caused by a heterozygous mutation in the TREX1 gene, which encodes a 3'-5' DNA exonuclease. Thus, familial chilblain lupus r...

The association of systemic lupus erythematosus and multiple myeloma is uncommon. We report two cases of systemic lupus erythematosus associated to multiple myeloma. The cases are discussed in the light of a review of the literature. The clinical, laboratory and radiographic findings of the patients, as well as the subsequent therapeutic approach are discussed. A systematic review of all the ot...

Objective The objective of this study was to investigate the association of clinical and renal disease activity with circulating sphingolipids in patients with systemic lupus erythematosus. Methods We used liquid chromatography tandem mass spectrometry to measure the levels of 27 sphingolipids in plasma from 107 female systemic lupus erythematosus patients and 23 controls selected using a desig...

INTRODUCTION To report on efficacy, tolerability and safety of rituximab in children with refractory autoimmune diseases. CASE PRESENTATION Five patients (juvenile dermatomyositis, Wegener's granulomatosis, systemic lupus erythematosus, myasthenia gravis and multiple sclerosis with systemic lupus erythematosus) were treated with rituximab and followed for a median time of 2.5 years. Two patie...

Few patients with systemic lupus erythematosus have features of verrucous (hypertrophic) lupus erythematosus. A 29-year-old Caucasian woman with a 7-year history of systemic lupus erythematosus developed painful verrucous plaques on the nose. Erythematous, raised, indurated, hyperkeratotic plaques localized on the dorsa of the distal parts of the toes and over the interphalangeal joints of her ...

how to cite this article: shiari r. neurologic manifestations of childhood rheumatic diseases.  iran j child neurol autumn 2012; 6(4): 1-7. children with rheumatic disorders may have a wide variety of clinical features ranging from fever or a simple arthritis to complex multisystem autoimmune diseases. information about the prevalence of neurological manifestations in children with rheumatologi...

background : progression of systemic lupus erythematosus (sle) could be due to oxidative stress especially through reactive oxygen species (ros). detoxification of ros is largely performed by glutathione s-transferases (gsts), therefore polymorphisms of gstm1, gstt1 and gstp1 genes which decrease enzymes activity could affect sle susceptibility. the aim of this study was to determine the effect...

background and objectives: bone marrow necrosis (bmn) is a rare and ominous complication of wide variety of diseases including hematologic malignancy. this study was performed to identify frequency and the underlying associated diseases of marrow necrosis. materials and methods: in this descriptive study, totally 850 bone marrow trephine biopsies related to living patients at the pathology depa...